2018 台北醫學大學藥學院教師研究專長簡介

劉景平教授 Prof. Jing-Ping Liou
Medicinal and Organic Chemistry
Design and synthesis of novel small molecular compounds bearing biological
functions.
Representative Publications
 Discovery and Development of small molecules towards IND
 Structure optimization through rational drug design
 Total Synthesis of natural products and its intelligent modification
1. Lee HY, Nepali K, Huang FI, Chang CY, Lai MJ, Li YH, Huang HL, Yang CR*, Liou J. P.*. (N-Hydroxycarbonylbenylamino)quinolines as
Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo. J. Med. Chem. 2018 Jan 26.
PMID: 29304284.
2. Liu, Y. M.; Nepali, K.; Liou, J. P.* Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. J. Med. Chem.
2017, 60, 527-553.
3. Lai, M. J.; Lee, H. Y.; Chuang, H. Y.; Chang, L. H.; Tsai, A. C.; Chen, M. C.; Huang, H. L.; Wu, Y. W.; Teng, C. M.; Pan, S. L.; Liu, Y. M.;
Mehndiratta, S.; Liou, J. P.* N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of
Transcription 3 (STAT3) Signaling. J. Med. Chem. 2015, 58, 6549-58.
4. Lee, H. Y.; Tsai, A. C.; Chen, M. C.; Shen, P. J.; Cheng, Y. C.; Kuo, C. C.; Pan, S. L.; Liu, Y. M.; Liu, J. F.; Yeh, T. K.; Wang, J. C.; Chang, C. Y.;
Chang, J. Y.*; Liou, J. P.* Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit
antitumor activity in colorectal cancer HCT116 cells. J. Med. Chem. 2014, 57, 4009-22.
5. Lee, H. Y.; Pan S. L;Su, M. C., Liu, Y. M.; Kuo, C. C.; Chang, Y. T.; Wu, J. S.; Nien, C. Y.; Mehndiratta, S.;Chang, C. Y; Wu, S. Yi.; Lai, M. J.;
Chang, J. Y.*; Liou, J. P.* Furanylazaindoles: potent anticancer agents in vitro and in vivo. J. Med. Chem. 2013, 56, 8008-8018.
Research in our laboratory is focused on the design and synthesis of small
molecular compounds as anticancer. We have experience for handling all
preclinical studies toward IND, including CMC, DMPK, GLP toxicology and safety
pharmacology. Dr. Liou’s lab uses a knowledge-based drug design approach to
create new and patentable small molecular compounds bearing biological
functions. Two such compounds passed US IND and are entering the human
clinical trials phase.

陳香吟教授 Prof. Shawn Hsiang-Yin Chen, M.S., Pharm.D.
Clinical Pharmacy and Medication Management
Optimization the medication use and pharmacy service in clinical practice
Pharmacogenomics and pharmacoepidemiology on pulmonary medicine
Development and evaluation of new pharmacy practice models
Bioinformatics and cloud-based medication record
Dr. Chen completed her clinical research and practice training at University of Iowa. She has
served as the pharmacy director, Wanfang Medical Center for 12 years, establishing
complementary models of pharmacy care. She was the funding chairperson of clinical pharmacy
division, establishing the 6 year pharmacy education program at TMU School of Pharmacy.
Research in Dr. Chen’s laboratory is focused on optimizing the medication use in clinical settings.
Applying the skills of pharmacogenomics, pharmacovigilance and bioinformatics, she published
many articles on cisplatin-induced nephrotoxicity, tuberculosis agents induced hepatic injury,
medication errors prevention, formulary management, cost containment, medication
reconciliation, pharmacy informatics, opioid use and clinical pharmacy service (IV-to-PO service,
antocoagulation, and antibiotics stewardship) for documenting the value of pharmacy service.
1. Lee YY, Kuo LN, Chiang YC, JY Hou, Wu TY, Hsu MH, Chen HY*. Pharmacist Conducted Medcation
Reconciliation at Hospital Admission using Information Technology. International Journal of Medical
Informatics. 2013; 82: 522-7.
2. Liu HE, Bai KJ, Hsieh YC, Yu MC, Lee CN, Chang JH, Hsu HL, Lu PC, Chen HY*. Multiple analytical
approaches demonstrate a complex relationship of genetic and non-genetic factors with cisplatin- or
carboplatin-induced nephrotoxicity in lung cancer patients. BioMed Research International. 2014;
Article ID 937429, 1-9.
3. Chen CM, Kuo CN, Cheng KJ, Shen WC, Bai KJ, Wang CC, Chiang YC, Chen HY*. The Effect of Medication
Therapy Management Service Combined with a National PharmaCloud System for Polypharmacy
Patients. Computer Methods and Programs in Biomedicine, 2016; 134:109-19.
4. Lee YH, Brown DL, Chen HY*. Current Impact and Application of Abuse-Deterrent Opioid Formulations
in Clinical Practice. Pain Physician. 2017, 20:1003-1023.

張偉嶠教授 Prof. Wei-Chaio Chang
牛津大學生理解剖暨遺傳學研究所博士 (University of Oxofrd, DPhil)
成功大學藥理學研究所碩士 (National Cheng Kung University, MSc)
台北醫學大學藥學系學士 (Taipei Medical University, BS)
Pharmacogenomics/Immunogenomics and Personalized Medicine
 Genetic characterization of gene signatures to establish personalized therapy
 Immune repertoire profiling for immunotherapies of cancer and autoimmune diseases.
This laboratory is to conducting research to determine how we could utilize human genetic information to personalized therapy. The
current study in our laboratory is focusing on cancer and autoimmune diseases. Through next-generation sequencing, genomic
analysis and data mining, we expect to identify useful biomarkers (genetic polymorphisms/immune repertoire) that could be
translated into clinical tools. We hope the genetic information identified from our population help us to improve clinical diagnosis and
to facilitate the development of therapy.
Representative Publications (*corresponding authors)
1. Wong HS, Chang CM, Kao CC, Hsu YW, Liu X, Chang WC, Wu MS*, Chang WC*. V-J
combinations of T-cell receptor predict responses to erythropoietin in end-stage renal
disease patients. J Biomed Sci. 2017; 24(1):43.
2. Kuo HC, Wong HS, Chang WP, Chen BK, Wu MS, Yang KD, Hsieh KS, Hsu YW, Liu SF, Liu X,
Chang WC*. Prediction for Intravenous Immunoglobulin Resistance by Using Weighted
Genetic Risk Score Identified From Genome-Wide Association Study in Kawasaki Disease.
Circ Cardiovasc Genet. 2017; 10:e001625.
3. Wong HS, Chang CM, Liu X, Huang WC*, Chang WC*. Characterization of cytokinome
landscape for clinical responses in human cancers. Oncoimmunology. 2016;
5(11):e1214789.
4. Wong HS, Juan YS, Wu MS, Zhang YF, Hsu YW, Chen HH, Liu WM, Chang WC*. Integrative
bioinformatic analyses of an oncogenomic profile reveal the biology of endometrial cancer
and guide drug discovery. Oncotarget. 2016; 7(5):5909-23.
5. Wang JY, Sun J, Huang MY, Wang YS, Hou MF, Sun Y, He H, Krishna N, Chiu SJ, Lin S, Yang S*,
Chang WC*. STIM1 overexpression promotes colorectal cancer progression, cell motility
and COX-2 expression. Oncogene. 2015; 34(33):4358-67.

李仁愛教授 Prof. Jen-Ai Lee
Bio-Analytical Chemistry
Pharmaceutical Analysis
 D,L-lactate and D,L-3-hydroxybutyrate in tissue damage
 Differential proteomics in kidney damage
1. Huang YS et al., Accumulation of methylglyoxal and D-lactate in Pb-induced
nephrotoxicity in rats. Biomed Chromatogr. 2017;31:e3869.
2. Hsieh CL et al., Enantioselective and simultaneous determination of lactate
and 3-hydroxybutyrate in human plasma and urine using a narrow-bore
online two-dimensional high-performance liquid chromatography system. J
Sep Sci. 2018; doi: 10.1002/jssc.201701283.
3. Lin CE et al., Proteomics analysis of altered proteins in kidney of mice with
aristolochic acid nephropathy using the fluorogenic derivatization-liquid
chromatography-tandem mass spectrometry method. Biomed Chromatogr.
2018;32(3). doi: 10.1002/bmc.4127.
We utilize two-dimensional HPLC coupled with fluorescence detector (FD) to
determine the concentration of D,L-lactate and D,L-3-hydroxybutyrate in kidney
damage. Our results showed that urinary D-lactate level may reflect to renal
damage in several kidney disease models, such as aristolochic acid-induced
nephropathy and diabetic nephropathy.
In differential proteomics, the proteins of kidney were derivatized with a
fluorogenic reagent DAABD-Cl and then separated by FD-LC. After statistical
analysis, the significantly different peaks were collected and analyzed by nanoLC-
MS/MS for protein identification. The alternative proteins between normal and
kidney disease groups will be further used for finding out the candidates of renal
damage biomarker.
The column-switching HPLC system.
Normal Kidney disease
Alternative proteins
Protein identification
Candidate biomarkers
The strategy of differential proteomics.
NanoLC-MS/MS

吳介信教授 Prof. Chieh-Hsi Wu
Cardiovascular and Cancer Pharmacology
Pathological investigations and pharmacological interventions in restenosis and
cancer (angiogenesis and chemotherapy resistance)
1. Liao HF†, Pan CH†, Chou PY, Chen YF, Wu TS*, Sheu MJ*, Wu CH*. PLOS One.
2017, 12(9): e0185021.
2. Chung YL, Pan CH, Wang CCN, Hsu KC, Sheu MJ, Chen HF*, Wu CH*. J Nat
Prod. 2016, 79:1635-1644.
3. Wu CH, Pan CH, Lee CK, Sheu MJ, Liu FC, Wang GJ, Wu CH*. J Funct Foods.
2016, 24:173-182.
4. Pan CH, Lin WH, Chien YC, Liu FC, Sheu MJ, Kuo YH*; Wu CH*. Toxicol Appl
Pharmacol. 2015, 282, 215-226.
5. Sheu MJ, Lin HY, Yang YH, Chou CJ, Chien YC, Wu TS, Wu CH*. Mol Nutr Food
Res. 2013, 57, 1586-1597.
 Pathological mechanisms involved in restenosis progression
 Evaluations of bioactive compounds for applying in treatments of
restenosis, hyperlipidaemia, and cancer (angiogenesis and
chemotherapy resistance)
 Development of vascular drug-eluted stents
Differential expression proteins in
early stages of angioplasty-induced
neointimal hyperplasia.
Major research fields in our laboratory are included: (1) Exploration of pivotal
molecules involved in restenosis development by genomic and proteomic
analyzes, which help to identify the potential therapeutic targeting molecules
or disease-specific biomarkers for clinical diagnosis. (2) Evaluation of
pharmacological activities and mechanisms of natural herb-sourced bioactive
compounds in preventions of restenosis or hyperlipidaemia. (3) Developments
of anti-angiogenic agents with multiple anti-cancer mechanisms and candidate
compounds against chemotherapy resistance, which can help to improve the
issues on side effects and drug resistance of first-line chemotherapy drugs.
Anti-angiogenic and anti-tumor evaluations of K20E.
Antiobesity and antihyperlipidaemic effects of Yan-Sheng-
Yin (YSY), a Chinese natural dietary supplement.
Molecular docking analysis of
matrix metalloproteinase-9 and
NCKU-21.

許秀蘊教授 Prof. Shiow-Yunn Sheu
Pharmaceutical Analysis and Bioactive Natural Products
Molecular Pharmacology of TCM on Mice Bone Formation and Neuron Protection
 Oxidized hyaluronic acid hydrogel for cartilage tissue engineering
 Stimulatory effects of TCM on mice bone formation
 Protective effects of TCM on mice astrocytes
1. Sheu SY, Chen WS, Sun JS, Lin FH, Wu T. Biological characterization of oxidized
hyaluronic acid/resveratrol hydrogel for cartilage tissue engineering.
J Biomed Mater Res Part A. 2013, (101A):3457-3466.
2. Sheu SY, Ho SR, Sun JS, Chen CY and Ke CJ Arthropod steroid hormone (20-
Hydroxyecdysone) suppresses IL-1β- induced catabolic gene expression in
cartilage. BMC Complementary and Alternative Medicine 2015, 15:1-8.
3. Sheu SY, Hong YW, Sun JS, Liu MH, Chen CY and Ke CJ. Radix Scrophulariae
extracts (harpagoside) suppresses hypoxia-induced microglial activation and
neurotoxicity. BMC Complementary and Alternative Medicine 2015, 15:324-332.
Schematic of the synthesis of the cross-link hyaluronic
acid containing resveratrol.
We have developed a hydrogel composed of oxidized hyaluronic acid and resveratrol
and incorporated it with cartilage cells to reverse chondrocyte degeneration.
One of the natural products, puerarin is a bone anabolic agent that exerts its osteogenic
effects through the induction of BMP-2 and NO synthesis, subsequently regulating
Cbfa1/Runx2, OPG, and RANKL gene expression. This effect may contribute to its
induction of osteoblast proliferation and differentiation, resulting in bone formation.
It was supported a possible role for astrocytes in the mediation of neuron protection by
coumestrol. An indirect extracellular signal-regulated kinase/c-Jun N-terminal kinase
signaling pathway to down regulate the expression of interleukin 1, interleukin 6, and
the tumor necrosis factor-alpha cytotoxic effect may act in concert with the proposed
direct ER-beta biosynthesis pathway to achieve a widespread, global protection of ER-
beta positive neurons.
FTIR spectra of (A) HA, (B) Oxi-HA, (C) Res, (D) HA-Res.

何秀娥教授 Prof. Hsiu-O Ho
Pharmaceutical Analysis, Biomaterials
Pharmaceutical Analysis and Drug Delivery Systems
 Pharmaceutical Analysis
 Development of biomaterials in drug delivery system
1. Jhan, H.J.; Liu, J.J.; Chen, Y.C.; Liu, D.Z.; Sheu, M.T.* and Ho, H.O*,
Nanomedicine – UK. 2014, 10(8) 1263.
2. Sheu, M.T.; Jhan, H.J.; Su, C.U.; Chen, L.J.; Chang, C.E.; Liu, D.Z.; and Ho, H.O*,
Colloids and Surfaces B: Biointerfaces, 2016, 143, 260.
3. Jhan, H.J.; Ho, H.O; Sheu, M.T.; Shen, S.C.; Ho, Y.S.; Liu, J.J, Patent No. US
9,364,545 B2, Jun. 14, 2016.
4. Sheu, M.T.; Wu, C.Y.; Su, C.Y.; Ho, H.O*, Scientific Reports, 2017, 7, 14609.
DOI:10.1038/s41598-017-15176-0.
A sensitive and specific liquid chromatographic/tandem mass spectrometric
(LC-MS/MS) method was developed and validated for quantifying total and
unbound docetaxel drug concentrations in plasma. The validated method was
successfully applied to a pharmacokinetic study of a docetaxel micelle formulation
in rat plasma after intravenous administration at a dose of 10 mg/kg. Docetaxel
micelles slowly released their drug payload, and protein-bound, unbound, and
micellar drug pools existed simultaneously. These various forms in plasma pools
were also measured in the study.
A thermosensitive injectable hydrogel (DH700KMF-15) composed of
nanocomplexes of doxorubicin (DOX) and hyaluronic acid (HA) was developed and
resulted in efficient growth inhibition of C26 colon cancer cells and it selectively
targeted the lymphatic system by the specific affinity of HA to the lymphatic
system in vivo. Besides DH700kMF-13.5/M-DocLF prepared with DH700KMF-15
incorporated with docetaxel (DOC)-loaded mixed micelles were developed to co-
deliver these two drugs, which can enhance the efficacy of cancer chemotherapy
with minimal side effects and reduced chemoresistance.
Tissue distributions of doxorubicin and docetaxel 72 h after SC and IT
administration of DH700KMF-15 or F-13.5/M-DocLF and DH700KMF-
13.5/M-DocLF into normal (A1 and B1) and CT-26 tumor-bearing
Balb/c mice (A2 and B2).
Docetaxel concentrations in various plasma pools after
intravenous administration of 10 mg/kg of docetaxel
micelles in SD rats

李慶國教授 Prof. Ching-Kuo Lee
Plant metabolism and Development of cosmetic ingredients.
 Discovery and Development of new cosmetic ingredients
 Plant Metabolism and Medicinal Phyto-compounds
 Application of Hyphenated Techniques in Drug Development
1. Chen, C. H.; Chang T. Chen, S. Y., Hsu, S. J.; Huang, H. W.; Lee, C. K. LWT - Food
Science and Technology 2017, 224, 411-419.
2. Lee, T. H.; Hsu, C. C.; Hsiao, G.; Fang, J. U.; Liu, W. M.; Lee, C. K. Planta Med 2016,
82, 698–704.
3. Wu, C. H.; Pan, C. H.; Lee C. K.; She, M. J.; Liu, F. C.; Wang , G. J.; Wu, C. H. Journal
of Functional Foods 2016, 24, 173–182.
4. Cheng, K. T.; Wang M. Y. S.;Chou, H. C., Chang, C. C.; Lee, C. K.; Juan, S. H.
Phytomedicine. 2015, 22, 641-647.
The development strategy of Natural product.
Beauty of nature
Research in our laboratory is focused on Development of new
cosmetic ingredients (Whitening, Anti-Aging); understand the
changes in plant metabolites in different environments; investigate
the effect of plant secondary metabolites and rapid analysis of life
body with MS (LC-MS/MS).

林淑娟教授 Prof. Shwu-Jiuan Lin
Medicinal Chemistry
Microbial Transformation
1. Kachingwe, B. H.; Uang, Y. S.; Huang, T. J.; Wang, L. H.; Lin, S. J.* Development and validation of an LC-MS/MS method for
quantification of NC-8 in rat plasma and its application to pharmacokinetic studies. J. Food Drug Anal. 2018, 26, 402408.
2. Lin, S. J.; Su, T. C.; Chu, C. N.; Chang, Y. C.; Yang, L. M.; Kuo, Y. C.; Huang, T. J. Synthesis of C-4-substituted steviol derivatives and their
inhibitory effects against hepatitis B virus. J. Nat. Prod. 2016, 79, 30573064.
3. Huang, T. J.; Yang, C. L.; Kuo, Y. C.; Chang, Y. C.; Yang, L. M.; Chou, B. H.; Lin, S. J.* Synthesis and anti-hepatitis B virus activity of C4
amide-substituted isosteviol derivatives. Bioorg. Med. Chem. 2015, 23, 720728.
4. Huang, T. J.; Chou, B. H.; Lin, C. W.; Weng, J. H.; Chou, C. H.; Yang, L. M.; Lin, S. J.* Synthesis and antiviral effects of isosteviol-derived
analogues against the hepatitis B virus. Phytochemistry 2014, 99, 107114.
Research in our group is involved the isolation and structure elucidation of novel organic
metabolites produced by microbial transformation of naturally occurring substances that
possess interesting structures and useful biological activities. The structures of the new
metabolites are elucidated primarily by spectroscopic analysis. 1D and 2D NMR experiments
play a pivotal role in the structure elucidation. Our current efforts also focus on the preparation
of chiral products by microbial transformation. These chiral products are then employed in the
syntheses of compounds for the discovery and development of new biological activities. We are
also actively collaborating with other researchers to identify and develop natural and synthetic
small-molecule based candidates for anti-virus, anti-inflammation and anti-tumor, and elucidate
their corresponding mechanisms of action. The experimental approach taken by our laboratory
is multidisciplinary, relying on the tools of synthetic chemistry, medicinal chemistry,
enzymology, biochemical pharmacology, X-ray crystallography, and spectroscopy to address our
goal.
1. The search for bioactive substances (isolation, structure elucidation, synthesis)
2. Synthesis of natural product-like compounds to develop new bioactive substances
3. Microbial transformations of naturally occurring substances
Effects of compound 6 on NF-B p65/p50, Erk 1/2,
and p38 MAPK protein expressions in Huh7 cells
that expressed the HBV genome

許明照教授 Prof. Ming-Thau Sheu
Pharmaceutics and Pharmaceutical Science
Drug dosage forms and drug delivery systems
 Oral controlled release dosage forms
 Lecithin-stabilized nanocarrier systems
 Albumin nanoparticles
In Sheu’s lab, phamaceutical nanotechnology includes self-assembly mixed polymeric
micelles (SAMPM), lecithin-stabilized nanocarrier systems (LSNS), protein-based (Albumin)
nanoparticles, and targeting of those pegylated nanocarriers by bispecific/trispecific
antibody have been my research’s interests. A new SAMPM system composed of
amphiphilic polymers and lipids and simply prepared by a thin-film method demonstrates
its potential benefit as a carrier for delivering two poorly water-soluble drugs. LSNS are a
pharmaceutically/nutraceutically drug nanocarrier comprising a lipid shell enclosing a
micellar core composed of an amphiphilic polymer with/without phospholipid or
emulsifier, wherein a pharmaceutically or nutraceutically active ingredient is disposed.
LSNS developed for carrying docetaxel has been conducted to demonstrate in vitro and in
vivo characteristics. Nanoparticle albumin-bound (Nab)-technology is a new technology
for anti-cancer drug delivery system which have been developed in my lab.
1. Jhan HJ, Liu JJ, Chen YC, Liu DZ, Sheu MT, Ho HO. Novel injectable thermosensitive
hydrogels for delivering Hyaluronic acid-doxorubucin nanocomplexes to locally treat
tumors. Nanomedicine-UK. 2015.
2. Ying-Chen Chen, Ray-Neng Chen, Hua-Jing Jhan, Der-Zen Liu, Hsiu-O Ho, Yong Mao,
Joachim Kohn, and Ming-Thau Sheu, (2015). Development and characterization of
acellular extracellular matrix scaffolds from porcine menisci for use in cartilage tissue
engineering. Tissue Eng. 21(9):971-986.
3. Ying-Chen Chen, Chia-Yu Su, Hua-Jun Jhan, Hsiu-O Ho, Ming-Thau Sheu (2015).
Physical characterization and in vivo pharmacokinetic study of self-assembling
amphotericin B-loaded lecithin-based mixed polymeric micelles. Int. J. Nanomed.
10:7265–7274.

廖嘉鴻教授 Prof. Jiahorng Liaw
Pharmaceutics
Drug and Gene Delivery with nano polymeri micelles and nanotubes

Blue light-induced Retinopathy
鄭幼文教授 Prof. Yu-Wen Cheng
Pharmacology and Toxicology
Drugs Development and Toxicity Test
 Drugs Development of Anti-mucositis and Anticancer.
 Drugs Development of Retinopathy and Age-Relative Macular
Degeneration Diseases.
 Toxicity test for food, drugs and cosmetics.
Research in our laboratory is focused on the development of the drugs as
the treatment of anticancer, anti-mucositis, anti-inflammatory and the
treatment for retinopathy and AMD. One of our newly developped compound
was granted from MOE showed significant mucositis inhibition on
chemotherapy induced whole body animal intestinal mucositis on C57BL/B6
mice. We also developed retinopathy animal models as platform for screening
light, drugs, toxins, and environmental agents induced eye diseases, especially
on dry-form AMD.
1. Lin CH, Wu MR, Li CH, Cheng HW, Huang SH, Tasi CH; Ho JD, Kang JJ; Hsiao
G; Cheng YW* (2017) Periodic exposure to smartphone-mimic low-
luminance blue light induces retina damage through Bcl-2/BAX-dependent
apoptosis. Toxicological Science.(Accepted).
2. Liao PL, Lin CH, Ho JD, Li CH, Tsai CH, Chiou GCY, KangJJ, Cheng YW*
(2017) Anti-inflammatory properties of shikonin contribute to improved
early-stage diabetic retinopathy. Scientific Report (Accepted).
3. Lin FL, Lin CH, Ho JD, Yen JL, Chang HM, George C.Y.Chiou; Cheng YW*,
Hsiao G* (2017).The natural retinoprotectant chrysophanol attenuated
photoreceptor cell apoptosis in an N-methyl-N-nitrosourea-induced mouse
model of retinal degeneration. Scientific Report.(Accepted)

Studies focus on the pharmacokinetics of drugs/TCMs and their related
hyperglycemic activity. We are particularly interested the naturally occurring
substances extracted from TCMs and they are consumed as dietary supplement.
The pharmacokinetic parameters would be then calculated and reveal the
disposition of compounds in the body/animal. By the calcium imaging technique,
we screen the herb extracts/its derivatives with [Ca2+]I changes in vitro to
investigate how herb extracts regulate calcium signals and how this related with
insulin release in pancreatic β-cells. The glucose uptake in skeleton
muscle/adipocytes and induced hyperglycemic animal experiment also utilized to
understand the hypoglycemic activity of these herbs. Recently, we join the cancer
drug discovery department to figure out stilbenes affect biological mechanism to
various cancers, such as ovarian, breast and colorectal cancer. We offer our
findings, not only to understanding the disposition of drug but also to elucidate
the mechanism and regulation of those compounds in vivo and studies,
that these natural occurring products may be beneficial for the concomitant in
disease treatment by their regulation of hypoglycemic and antiproliferation
effects.
何意副教授 Associate Prof. Yih Ho
Pharmacokinetics and Pharmaceutics
The Pharmacokinetics of natural occurring compounds
Representative Publications (
 The pharmacokinetics of drugs/TCMs and their interaction
 Potential natural products having hypoglycemic activity with insulin
release/glucose uptake properties.
 Pharmacophore modeling to design the potential enzyme
Inhibitors (cooperated with NTUT lab)
 Antiproliferation of stilbenes (cooperated with CBDD lab)
Y. Ho , Y-S Lin, H-L Liu , Y-J Shih , S-Y Lin , A Shih, Y-T Chin, Y-R Chen , H-Y Lin and P J.
Davis, ” Biological mechanisms by which antiproliferative actions of resveratrol are
minimized”, Nutrients 9, 1046-1056(2017)
Z-L Zhou, H-L Liu, J W. Wu, C-W Tsao, W-H Chen, K-T Liu and Y Ho, “ Computer-aided
discovery of potential inhibitors for transthyretin-related amyloidosis”, Journal of the
Chinese Chemical Society, 61(2), 263–273(2014)
The plasma glucose level and
increment AUC changes
following administration of
AFE analysis
[Ca2+]I change of EMF The best SB_Hypo1 and ERB-041
stilbenes
The pharmacophore model
of 5-reductase and FIT
mapped with model

吳建德副教授 Associate Prof. Jender Wu
Customized synthesis of small molecules possessing biological activities and
particular applications
 Synthesis of active metabolites.
 Design and synthesis of congeners or derivatives of active natural
products.
1. Wang KC, Cheng MC, Hsieh CL, Hsu JF, Wu JD*, Lee CK*. Forensic Sci Int. 2013,
224, 84-89.
2. Chen PY, Wu JD, Tang KY, Yu CC, Kuo YH, Zhong WB, Lee CK. Molecules. 2013, 18,
7600-7608.
3. Wu JD, Chien CC, Yang LY, Huang GC, Cheng MC, Lin CT, Shen SC, Chen YC. Chem
Biol Interact. 2011, 193, 3-11
In our laboratory, we focus on several research fields. The metabolites of the
abused drug, e.g. nimetazepam and nitrazepam, were synthesized as the
standard for medical and forensic uses.
We also synthesized different naphthoquinone derivatives and evaluated their
cytotoxicity and biological mechanisms. For example, 2-methyl-1,4-
naphthoquinone (vitamin K3), which belongs to the vitamin K family, is a
synthetic drug for the coagulation disorder. Vitamin K3 and its oxidized form,
menadione-2,3-epoxide, were toxic against glioma cells. They are able to induce
apoptosis in human glioma cells by activation of ROS-dependent ERK and JNK
protein phosphorylation. Further development of naphthoquinone-based
anticancer studies as well as other applications other than biological purposes
are currently undergoing.

林美香副教授 Associate Prof. Mei-Hsiang Lin
Design and synthesis of novel small molecular compounds bearing biological
functions.
 Discovery and Development of small molecules
 Structure optimization through rational drug design
 Isolation and modification of natural products
1. 1. Lin, H. C.; Lin, M. H.; Liao,J. H.; Wu, T. H.; Lee, T. H.; Mi, F. L.; Wu, C. H.; Chen, K. C.;
Cheng, C. H.; and Lin, C. W.* J. Agr. Food Chem. 2017, 65, 51-59.
2. Chiang, L. L.; Tseng, I. J.; Lin, P. Y.; Sheu, S. Y.; Lin, C. T.; Hsieh, Y. H.; Lin, Y. J.; Chen, H. I.;
and Lin, M. H.* Molecules 2016, 12, 100.
3. Tseng, I. J.; Lin, P. Y.; Sheu, S. Y.; Tung, W. N.; Lin, C. T.; and Lin, M. H.* J. Chin. Chem.
Soc. 2015, 62, 59-63.
4. Lin, M. H.; Cheng, C. H.; Chen, K. C.; Lee, W. T.; Wang, Y. F.; Xiao, C. Q.; and Lin, C. W.*
Chem-Biol. Interact. 2014, 218, 42-49.
Research in our laboratory is focused on the design and synthesis of small molecular compounds as anti-diabetes, anti-inflammatory
agents, and Anti-Cataract Agents. The anti-inflammatory activities of these derivatives were evaluated by means of inhibiting NO
production in LPS-induced RAW 264.7 cells. Five derivatives exhibited low micromolar levels of anti-inflammatory activities, and these
derivatives also protected DNA against hydroxyl radical attack. Coumarin derivative 8 was the most potent derivative among those
tested herein against NO production in LPS-induced RAW 264.7 cells with an IC50 value of 7.6 mM, and it effectively reduced the
hydroxyl radical production by 50% at 100 mM in the electron spin resonance study. Coumarin 7, 6-benzoyl-5,6-dihydroxy-4-phenyl-
chromen-2-one, was found to have the most potent activity in protecting porcine g-crystallin against UVC insults. Results of
fluorescence assays indicated that compound 7 was capable of decreasing the loss of intensity while lens crystallins and DNA PUC19
were irradiated with UVC. Presence of compound 7 decreased hydroxyl radical levels determined by probe 1b and the free iron
concentrations determined by Ferrozine reagent. The chelation assay showed that compound 7 was chelated to metal via 6-CO and 5-
OH on the benzopyrone ring. The observed protective effects of compound 7 towards crystallins from insults of UVC and freeradicals
may be due to its iron-chelating activity and its peak absorption at 254 nm.

梁文俐副教授 Associate Prof. Wen-Li Liang
Chinese herbal medicine and Natural plant research
1. Antibacterial Activity
2. Quality control of Chinese herbal medicines
3. Chinese herbal medicine processing
4. Study on the Prescription of Traditional Chinese Medicine
1. Yun-Yang Lee, Hsieh-Yu Li, Shih-Jiuan Chiu, Wen-Li Liang, Pi-Li Yeh and Ying-Ling
Liu (2015), Redox reaction mediated direct synthesis of hierarchical flower-like
CuO spheres anchored on electrospun poly(vinylidene difluoride) fiber surfaces
at low temperatures, RSC Adv., 5, 100228–100234
2. Lee Tzong-Huei, Tsai Yow-Fu, Huang Tzu-Tien, Chen Pi-Yu, Liang Wen-Li*, Lee
Ching-Kuo* (2012), Heptadecanols from the leaves of Persea americana var.
Americana, Food Chemistry, 132, 921–924.
3. Guei-Jane Wang, Wen-Li Liang, Yu-Ming Ju, Wen-Bin Yang, Ya-Wen Chang, and
Tzong-Huei Lee (2012). Inhibitory Effects of Terpenoids from the Fermented Broth
of the Ascomycete Stilbohypoxylon elaeicola YMJ173 on Nitric Oxide Production
in RAW264.7 macrophages, Chemistry & Biodiversity(9)131-138

邱士娟副教授 Associate Prof. Shih-Jiuan Chiu
School of Pharmacy, Taipei Medical University
Pharmaceutics/Drug and/or Gene Delivery, Dosage Form Design
 Delivery of gene/siRNA/antisense agents by nanoparticles or liposomes
 Targeted drug/gene/antisense delivery systems
 Nanoparticle design and synthesis
 Development of novel biomaterials for drug/gene/antisense delivery
1. Chiu SJ, Lin CY, Chou HC, Hu TM (2016). Silica ouzo effect: Amphiphilic drugs facilitate nanoprecipitation of polycondensed
mercaptosilanes, Langmuir (32):211-220
2. Wang MR, Chiu SJ, Chou HC, Hu TM (2015). An efficient S-NO-polysilsesquioxane nano-platform for the co-delivery of nitric oxide
and an anticancer drug. Chemical Communications (51):15649-15652.
3. Chou HC, Chiu SJ, Hu TM (2015). LbL assembly of albumin on nitric oxide-releasing silica nanoparticles using Suramin, a polyanion
drug, as an interlayer linker. Biomacromolecules (16):2288-2295.
4. Chou HC, Chiu SJ, Liu YL, and Hu TM (2014). Direct Formation of S-Nitroso Silica Nanoparticles from a Single Silica Source. Langmuir
(30): 812-822
5. Chiu SJ, Wang SY, Chou HC, Liu YL, Hu TM (2014). Versatile synthesis of thiol- and amine-bifunctionalized silica nanoparticles based on
the ouzo effect. Langmuir (30):7676-7686
Research in our laboratory is focused on delivery of gene/antisense to tumors and development of targeted
drug delivery systems by nanoparticles or liposomes. These nanoparticles serve as carriers for various
therapeutic agents, including small molecules like chemotherapeutic agents and large molecules like protein,
peptides, and nucleic acids such as plasmid DNA, antisense oligonucleotides, siRNA, and miRNA to enhance
their therapeutic efficacy in patients. Our effort is mainly focused on optimizing nanoparticle formulations
based on rational design and directed at clinical applications.

李學耘助理教授 Assistant Prof. Hsueh-Yun Lee
 Rational design and development of small molecules
 Computer-aided design of bioactive compounds
 Lead optimization
 Organic synthesis / total synthesis of natural products
We are interested in designing and synthesizing novel molecules with
promising biological activity, for example, anticancer and neurological
activity. Recently, we have developed some selective HDAC inhibitors which
have potential antiproliferative activity and are able to ameliorate the
symptoms of Alzheimer’s disease. We also utilize modern technologies such
as computer modeling, microwave irradiator, and parallel synthesis to
design novel structures and to speed up our research.
1. Lee, H. Y.; Nepali, K.; Huang, F. I.; Chang, C. Y.; Lai, M. J.; Li, Y. H.; Huang, H. L.;
Yang, C. R.; Liou, J. P.* J. Med. Chem. 2018, Just Accepted.
2. Lee, H. Y.; Lee, J. F.; Kumar, S.; Wu, Y. W.; HuangFu, W. C.; Lai, M. J.; Li, Y. H.;
Huang, H. L.; Kuo, F. C.; Hsiao, C. J.; Cheng, C. C.; Yang, C. R.*; Liou, J. P.* Eur. J.
Med. Chem. 2017, 125, 1268-1278.
3. Lee, H. Y.; Chang, C. Y.; Su, C. J.; Huang, H. L.; Mehndiratta, S.; Chao, Y. H.; Hsu, C.
M.; Kumar, S.; Sung, T. Y.; Huang, Y. Z.; Li, Y. H.; Yang, C. R.*; Liou, J. P.* Eur. J.
Med. Chem. 2016, 122, 92-101.
4. Lee, H. Y.; Kumar, S.; Lin, T. C.; Liou, J. P.* J. Nat. Prod. 2016, 79, 1170-1173.
5. Nepali, K.; Kumar, S.; Huang, H. L.; Kuo, F. C.; Lee, C. H.; Kuo, C. C.; Yeh, T. K.; Li, Y.
H.; Chang, J. Y.; Liou, J. P.; Lee, H. Y.* Org. Biomol. Chem. 2015, 14, 716-723.

謝堅銘助理教授 Assistant Prof. Chien-Ming Hsieh, Ph.D.
Pharmaceutics and Biopharmaceutics
1. CM Hsieh, W Warisnoicharoen, RK Patel, F Kianfar, and MJ Lawrence. (2017, Mar.). Oil-in-water
microemulsions stabilized by 3-(N,N- dimethylalkylammonio)propanesulfonate surfactants of varying alkyl
chain length: Solubilisation of testosterone propionate. International Journal of Pharmaceutics. 525(1):1-4.
2. Po-Chun Peng*, Chien-Ming Hsieh*, Chueh-Pin Chen, Tsuimin Tsai, and Chin-Tin Chen. (2016, Nov.).
Assessment of photodynamic inactivation against periodontal bacteria mediated by a chitosan hydrogel in a
3-D gingival model. International Journal of Molecular Sciences, 17(11),1821. *co-first authors.
3. Ming-Thau Sheu, Chien-Ming Hsieh, Ray-Neng Chen, Po-Yu Chou, Hsiu-O Ho. (2015, Dec). Rapid-onset
sildenafil sublingual drug delivery systems: in vitro evaluation and in vivo pharmacokinetic studies in rabbits.
International Journal of Pharmaceutics. 105(9):2774-81.
4. Chien-Ming Hsieh, Yu-Wen Huang, Ming-Thau Sheu, Hsiu-O. Ho. (2014, Mar). Biodistribution profiling of the
chemical modified hyaluronic acid derivatives used for oral delivery system. International Journal of Biological
Macromolecules, 64, 45– 52.
 Pharmacokinetic & Formulation design
 Photodynamic Therapy
 Nanomedicine
Dr. Hsieh’s research group focuses on improving the delivery of low molecular weight drugs and
biomolecules such as DNA and siRNA using a range of novel and conventional surfactant/polymer and lipid
molecules. Particularly on understanding how the structure of a molecule influences the molecular
architecture of the delivery vehicle it forms and its fate in the target cell. In addition, he has a strong
collaboration with research group in Biochemical Science and Technology Department of National Taiwan
University working on antimicrobial photodynamic inactivation (PDI). He has published on a diverse range
of topics in drug delivery systems both significant amounts of data as well as analytic advances.
Dr. Hsieh is a pharmacist, having completed a BSc in Pharmacy at TMU. He gained a PhD in Pharmaceutical
Science from King’s College London under the supervision of Prof. Jayne Lawrence and Dr. Cecile Dreiss.
Biodistribution profiling of the
chemical modified hyaluronic acid

Blue light-induced Retinopathy
鄭慧文教授 Prof. David Hui-Wen Cheng
美國加州大學藥學博士 (University of California, USA)
台灣大學藥學士 (National Taiwan University, BS)
Pharmaceutical Management, Regulatory Affairs
 Pharmaceutical Marketing.
 Pharmaceutical Regulations.
 Pharmaceutical R&D Management.
1. Lin CH, Wu MR, Li CH, Cheng HW, Huang SH, Tasi CH; Ho JD, Kang JJ; Hsiao G;
Cheng YW (2017) Periodic exposure to smartphone-mimic low-luminance blue
light induces retina damage through Bcl-2/BAX-dependent apoptosis.
Toxicological Science.(Accepted).
2. Lin HC,Hsiao YT, Lin HL, Uang YS, Cheng HW, Wang Y and Wang LH.(2016) The use
of proton pump inhibitors decreases the risk of diabetes mellitus in patients with
upper gastrointestinal disease A population-based retrospective cohort study.
Medicine 95: 28 (1-5)
3. Lin CH; Liao PL, Hsiao G, Li CH, Huang SH, Tsai CH, Wu MR; Ho JD, Cheng HW,
Cheng YW (2015) Long-term fluorometholone topical use induces ganglion cell
damage in rats analyzed with optical coherence tomography. Toxicological
Science. 147(2):317-325.
4. Lin HC, Kachingwe BH, Lin HL, Cheng HW, Uang YS, Wang LH (2014) Effects of
Metformin Dose on Cancer Risk Reduction in Patients with Type 2 Diabetes
Mellitus: A 6-Year Follow-up Study. Pharmacopherapy.34(1):36-45.
5. Cheng HW, Lee KC, Cheah KP, Chang ML, Lin CW, Li JS, Yu WY, Liu ET, Hu CM
(2013) Polygonum viviparum L. inhibits the lipopolysaccharide-induced
inflammatory response in RAW264.7 macrophages through haem oxygenase-1
induction and activation of the Nrf2 pathway. Journal of Science and Food
Agriculture.(93):491-497.

吳姿樺教授 Prof. Tzu-Hua Wu, Ph.D.
Department of Clinical Pharmacy, Taipei Medical University
Biochemistry and Pharmacotherapeutics
Clinical Pharmacy & Therapeutics Drug Utilization Evaluations and Managements.
Representative Publications (2012-now)
 Therapeutic drug monitoring and clinical pharmacokinetics in psychiatrics and
blood disorders
 Biochemical pharmacology of Chinese herbal medicine in cataract and infertility
 Pharmaceutical care and managements
1. Lu MY, Lin TH, Chiang PH, Kuo PH, Wang N, Wu WH, Lin KH, Wu TH*. Deferasirox-Iron
Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in β-Thalassemia
Major. Ther Drug Monit. 2017 39(2):185-191.
2. Liao JH, Huang YS, Lin YC, Huang FY, Wu SH, Wu TH*. Anticataractogenesis Mechanisms of
Curcumin and a Comparison of Its Degradation Products: An in Vitro Study. J Agric Food
Chem. 2016; 64(10):2080-6.
3. Lu ML, Wu YX, Chen CH, Kuo PT, Chen YH, Lin CH, Wu TH*. Application of plasma levels of
olanzapine and n-desmethyl-olanzapine to monitor clinical efficacy in patients with
schizophrenia. PLoS One 2016;11(2):e0148539.
4. Lu MY, Wang N, Wu WH, Lai CW, Kuo PH, Chiang PH, Lin KH, Wu TH*. Simultaneous
determination of plasma deferasirox and deferasirox-Iron complex using an HPLC-UV system
and pharmacokinetics of deferasirox in patients with β-Thalassemia major: once-daily versus
twice-daily administration. Clin Ther. 2015 S0149-2918(15)00845-0.
5. Chen YC, Pan LC, Lai CW, Chien YS Wu TH*. Silymarin and protein kinase A inhibitor modulate
glucose-mediated mouse sperm motility: An in vitro study. Reprod Biol. 2015;15(3):172-7.
Therapeutic Drug Monitoring on correlation between
metabolic syndromes and levels of clinical
drug/metabolite by HPLC-ECD system in patients.
Dr. Wu’s researches focus on Therapeutic Drug Monitoring research particularly in
the field of Neuropsychiatry, Pediatrics and Biochemical nutrition to improve patients’
therapeutic outcomes. Being a director for Pharmacist Association, Dr. Wu not only
considers patients’ benefits but also put her efforts on supporting systems to facilitate
performance of pharmacists. She published more than 30 research articles before
2016 and also serves as reviewers for several journals including in managed care field.
PLOS ONE 2013 8(5):e65719.
Proposed role for curcumin and its effective degradation
as an anti-cataract drugs. J Agric Food Chem. 2016

陳世銘副教授 Associate Prof. Shih-Ming Chen, Ph.D.
1. Lin, C.E.,Chang, W.S.,Lee, J.A., Chang, T.Y.,Huang, Y.S.,Hirasaki Y, Chen HS, Imai K, Chen SM. Proteomics analysis of
altered proteins in kidney of mice with aristolochic acid nephropathy using the fluorogenic derivatization–liquid
chromatography–tandem mass spectrometry method . Biomedical Chromatography .2017 ;(2014):1-9
2. Huang YS,Li YC,Tsai PY,Lin CE,Chen CM,Chen SM , Lee JA. Accumulation of methylglyoxal and D‐lactate in
Pb‐induced nephrotoxicity in rats . Biomedical Chromatography .2016 ;(2016):1-10
3. Chou CK,Li YC,Chen SM,Shih YM,Lee JA. Chitosan Prevents Gentamicin-Induced Nephrotoxicity via a Carbonyl
Stress-Dependent Pathway . BioMed Research International .2015
Our team developed the various nephropathy mice
models, including aristolochic acid nephropathy, cisplatin-
induced nephrotoxicity, and accelerated nephrotoxic
serum nephritis, to discover the natural products or other
pharmaceutical drugs which could be used for kidney
diseases. Generally, our research are composed of
biochemistry analysis, histopathological examination,
immunohistochemistry, and pharmacokinetic study.
Recently, we are trying to expolore the biomarkers for
diagnozing kidney disease.
 Clinical pharmacy
 Pharmacotherapy of Kampo Medicine
 Nephrological pharmacology
Normal group AA group

Dr. Yu (Nancy) Ko obtained her B.Sc. in Pharmacy from the National Taiwan University
and holds a Masters degree in Pharmacy Administration from the University of Illinois at
Chicago. She received her Ph.D. in Pharmaceutical Economics, Policy, and Outcomes
Research from the University of Arizona and was a founding member of the Singapore
chapter of the International Society for Pharmacoeconomics and Outcomes Research
(ISPOR). Dr. Ko’s research experience and publications lie in the areas of
pharmacoeconomics, psychometrics, and patient-reported outcomes. She is collaborating
with local pharmacists and other health care providers on several research projects that
aim to improve the safety and cost-effectiveness of drug use in Taiwan.
戈鈺副教授 Associate Prof. Yu (Nancy) Ko, Ph.D.
Pharmaceutical Economics, Policy, and Outcomes Research
 Pharmacoeconomics
 Drug utilization review
 Health service research
 Psychometrics
 Patient-reported outcomes (PROs)
1. Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y. Patient-reported health preferences of anticoagulant-related outcomes. J Thromb
Thrombolysis. 2015;40(3):268-73.
2. Ng CS, Toh MP, Ng J, Ko Y. Direct medical cost of stroke in Singapore. Int J Stroke. 2015;10 Suppl A100:75-82.
3. Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke
prevention in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2014;28:575-85.
4. Ko Y, Gwee YS, Huang YC, Chiang J, Chan A. Costs and length of stay of drug-related hospital admissions in cancer patients. Clin Ther.
2014;3:588-92.
5. Ko Y, Lo NN, Yeo SJ, Yang KY, Yeo W, Chong HC, Thumboo J. Comparison of the responsiveness of the SF-36, the Oxford Knee Score,
and the Knee Society Clinical Rating System in patients undergoing total knee replacement. Qual Life Res. 2013;22:2455-9.
6. Ko Y, Tan SL, Chan A, Wong YP, Yong WP, Ng RCH, Lim SW, Salim A. Prevalence of the co-prescription of clinically important
interacting drug combinations involving oral anticancer agents: a retrospective database study. Clin Ther. 2012;34:1696-704.

王莉萱副教授 Associate Prof. Li-Hsuan Wang
Clinical pharmacokinetic, Pharmacoepidemiology and Clinical Pharmacy and
Therapeutics
 Natural product and drug interaction
 Pharmacoepidemiology and therapeutic risk management
 Nonclinical pharmacokinetics study
 Pharmacokinetic/Pharmacodynamic study
1. Lin HC, Daimon M, Wang C-H, Ho Y, Uang YS, Chiang S-J, Wang L-H (2017). Allopurinol, Benzbromarone, and
Risk of Coronary Heart Disease in Gout Patients: a Population-Based Study. International Journal of
Cardiology 233: 85-90.
2. Lin HC, Hsiao YT, Lin HL, Uang YS, Cheng HW, Wang Y, Wang L-H (2016). The Use of Proton Pump Inhibitors
Decreases the Risk of Diabetes Mellitus in Patients with Upper Gastrointestinal Disease. A Population-Based
Retrospective Cohort Study. Medicine 95 (28): e4195.
3. Wang L-H, Liu CK, Chen CH, Kao LT, Lin HC, Huang CY (2016). No increased risk of coronary heart diseases for
patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men. Andrology 4
(1): 128-132.
4. Huang CY, Chung SD, Kao LT, Lin HC, Wang L-H (2015). Statin use is associated with bladder pain
syndrome/interstitial cystitis: A population-based case-control study. Urologia Internationalis 95 (2): 227-232
5. Chiang SJ, Daimon M, Wang L-H, Hung M-J, Chang N C, Lin HC (2015). Association between mitral value
prolapse and open-angle glaucoma. Heart 101: 609-615.
6. Chung S-D, Chen C-H, Hung S-H, Lin H-C, Wang L-H (2015). A Population-Based Study on the Association
between Statin Use and Sudden Sensorineural Hearing Loss. Otolaryngology-Head and Neck Surgery 152 (2):
319-325.

吳宗軒副教授 Associate Prof. Chung-Hsuen Wu
Pharmacoepidemiology and outcomes research
 Pharmacoepidemiology (藥物流行病學) and pharmacoeconomics (藥事經濟學)
 Medication adherence (服藥順從性) and health service research among pregnant
women and older patients with chronic diseases
 Pharmaceutical outcomes research using large administrative data and complex sample
survey data (資料庫研究)
1. Cheng HT, Lin FJ, Erickson SR, Hong JL, Wu CH.* (2017) The Association between the Use of Zolpidem and the Risk of Alzheimer's
Disease among Older People. Journal of the American Geriatrics Society, 65(11): 2488-2495.
2. Chung S, Yeh T, Wu CH.* (2017) Trend and Pattern of Herb and Supplement Use among Pregnant Women in the United States:
Findings from the 2002, 2007, and 2012 US National Health Interview Surveys. The American Journal of Obstetrics and Gynecology,
216(2): 189-190.
3. Li CY, Erickson SR, Wu CH.* (2016) Metformin Use and Asthma Outcomes among Patients with Concurrent Asthma and Diabetes.
Respirology, 21 (7): 1210-1218.
Dr. Wu’s research interests focus on medication-related health outcomes, including medication adherence, persistence, and health
resource utilization among patients with chronic diseases. With multidisciplinary training in pharmacy, health policy and administration,
and health services research, Dr. Wu has extensive experience working with large health claims data and complex sample survey data to
conduct pharmaceutical outcomes research. He is familiar with administrative claims data such as National Health Insurance Research
Database (NHIRD) in Taiwan, MarketScan® Commercial Claims data, MarketScan® Multi-States Medicaid Administrative data, and
Humana Medicare and Commercial Claim Data as well as complex survey data such as the Medical Expenditure Panel Survey (MEPS),
National Comorbidity Survey-Replication (NCS-R), and National Health Interview Survey (NHIS).
Prior to his current appointment, Dr. Wu was a Human/UNC Pharmaceutical Outcomes Post-Doctoral Research Fellow in the Eshelman
School of Pharmacy at the University of North Carolina – Chapel Hill, U.S.A. He had his Bachelor of Pharmacy degree from National
Taiwan University and his Master degree in Health Policy and Administration in Washington State University U.S.A. Dr. Wu graduated
from University of Michigan U.S.A., College of Pharmacy in 2010 and had his Ph.D. degree in Clinical, Social, and Administrative
Pharmacy.

卓爾婕副教授 Associate Prof. Er-Chieh Cho, MSc., DPhil.
Molecular Cancer Biology, Translational Medicine, and Nanomedicine
1. Cho EC, Zheng S, Munro S, Liu G, Carr SM, Moehlenbrink J, Lu YC, Stimson L, Khan O, Konietzny R,
McGouran J, Coutts AS, Kessler B, Kerr DJ, Thangue NB. Arginine Methylation Controls Growth
Regulation by E2F-1. EMBO J. 2012 Feb 10;31(7):1785-97.
2. Cho EC, Kuo ML, Liu X, Yang L, Hsieh YC, Wang J, Cheng Y, Yen Y. Tumor suppressor FOXO3 regulates
ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients. Oncotarget.
2014 Jul 15;5(13):4834-44.
3. Hsieh YC, Cho EC, Tu SH, Wu CH, Hung CS, Hsieh MC, Su CT, Liu YR, Lee CH, Ho YS, Chiou HY. MSH2
rs2303425 Polymorphism is Associated with Early-Onset Breast Cancer in Taiwan. Ann Surg Oncol.
2017 Feb;24(2):603-610. doi: 10.1245/s10434-016-5168-5.
4. Yang KC, Zheng JH, Chen YL, Lee KC, Cho EC. Carboxyfullerene decorated titanium dioxid
enanomaterials for reactive oxygen species scavenging activities. RSC Adv. 2016(6):53025-53033.
A model of protein arginine
methyltransferase PRMT5-mediated
methylation on E2F1 response
regulation.
Research in our laboratory is focused on molecular cancer biology in translational
medicine and biomedical applications of nanomaterials. The molecular mechanisms of
tumor development has been researched by studying protein post-translational
modifications of key cellular regulators such as E2F1 and p53; the transcriptional
regulation of CREB in leukemogenesis has also been studied; tumorigenesis in colon
cancer is currently under investigation in our group; our laboratory is also cooperating
with scientists in material science and bioinformatics. Undergoing projects include
evaluation and development of different nanomaterials in biomedical application.
E2F1 level PRMT5 level
E2F1 methylated and
transcription suppressed
E2F1-induced apoptosis
increased
 Biomarker development
 Tumorigenesis of colon cancer
 Toxicology study and development of nanomaterials in biomedical applications

Representative publications
 Interprofessional Care
 Chronic Disease Management
 Evaluation of Pharmacy Services
 Factors Influencing Medication Use
 Pharmacy Education
1. Patterson BJ, Chang EH, Witry MJ, Garza OW, Trewet CB. Pilot evaluation of a continuing professional development tool for
developing leadership skills. Research in Social & Administrative Pharmacy. 2013 Mar-Apr;9(2):222-9.
2. Doucette WR, Chang EH, Pendergast JF, Wright KB, Chrischilles EA, Farris KB. Development and initial assessment of the Medication
Use Self Evaluation (MUSE) Tool. Clinical Therapeutics. 2013 Mar;35(3):344-50.
3. Patterson BJ, Garza OW, Witry MJ, Chang EH, Letendre DE, Trewet CB. A leadership elective course developed and taught by
graduate students. American Journal of Pharmaceutical Education. 2013 Dec;77(10):223.
Dr. Chang’s research group focuses on pharmacy practice and education. We believe
that practice-based research is important for expanding pharmacist roles and advancing
the pharmacy profession. In particular, we are interested in understanding patient
perceptions of medication use and evaluating interventions to improve patient
outcomes. Our group specializes in qualitative methods and mixed quantitative and
qualitative methods. Recent projects involve medication adherence, health literacy,
medication reconciliation, and controlled drugs policy in Taiwan.
In addition to the faculty appointment, Dr. Chang serves as the Deputy Director of
Department of Pharmacy, Taipei Municipal Wanfang Hospital (Managed by Taipei
Medical University, TMU). Prior to arriving at TMU, Dr. Chang received her Ph.D. in
Pharmaceutical Socioeconomics from the University of Iowa and Doctor of Pharmacy
from the Ohio State University.
張雅惠助理教授 Assistant Prof. Elizabeth H. Chang
Clinical, Social and Administrative Pharmacy

鄭桂如講師 Lecturer Kuei-Ju Cheng, Ph.D.
Clinical research and projects with focus on:
 Cost saving on pharmacist interventions
 Medication utilization evaluations
 Development of informatics systems in hospital pharmacy
 Development of informatics systems in pharmacy education
1. Yu-Hsuan Yen , Li-Na Kuo , Min-Huei Hsu , Yu-Chuan Li , Kuei-Ju Cheng. “Evaluation of
the electronic adverse drug event management system.” Journal of Experimental and
Clinical Medicine(JECM). 2010 Dec；2（6）：287-291
2. Yu-Hsuan Yen, Hsiang-Yin Chen, Leu Wuan-Jin, You-Meei, Lin, Wan Chen Shen, Kuei-Ju
Cheng. “Clinical and Economic Impact of a Pharmacist-managed IV-to-PO Conversion Service
for Levofloxacin in Taiwan.” International Journal of Clinical Pharmacology and Therapeutics.
2012; 50(2): 136-141
3. Yu-Ting Yeh*, Hsiang-Yin Chen*, Kuei-Ju Cheng, Su-An Hou,Yu-Hsuan Yen, Chien-Tsai Liu.
“Evaluating an Online Pharmaceutical Education System for Pharmacy Interns in Critical Care
Settings”Computer Methods and Programs in Biomedicine

石榴皮
紅球薑
蛇床子
威靈仙
白朮
鹿茸
紅花大黃
王靜瓊教授 Prof. Ching-Chiung Wang
Pharmacology of Traditional Chinese Medicine
Develop the new botanical drugs based on theory of TCM, phytochemistry and
pharmacology
1. Tseng, S.H.; Sung, C.H; Chen, L. G.; Laie, Y. J.; Chang, W. S.; Sung, H. C.;
Wang, C. C.* Journal of Ethnopharmacology. 2014, 151, 352-360.
2. Lee Y.W., Chen T.L., Shih Y.R. Vernon, Tai C.L., Chang C.C., Liang H.H., Tseng
S.H., Chien S.C., Wang C.C.* Cancer, 2014, 1338-1344.
3. Chen LG, Jan YS, Tsai PW, Norimoto H, Michihara S, Murayama C, Wang C.
C.*. J Agric Food Chem, 2016, 64(11):2254-62.
4. Chen LG, Su PJ, Tsai PW, Yang LL, Wang C. C.*. Planta Medica. 2017
(83):151-157.
 Investigate the processed methods of TCM
 Investigate the philosophy of TCM prescription
 Investigate the pharmacology of TCM
The above herbals were studies in our laboratory.
Our researches are focus on evidence-based traditional Chinese medicines
(TCM) and then translate the findings to biopharmaceutical products. Firstly, the
processed methods of TCM are explored. We investigate the correlation of
phytochemistry and pharmacology after processed-TCM and expect to control the
quality of the TCM. Secondly, the philosophies of TCM prescriptions are explored.
Most TCM prescriptions include more than four herbs, and each herb has its
special function. Phytochemicals contained in TCM prescriptions were used to
discuss the clinical application and expect to understand the reasons of TCM
prescription compositions. Finally, according to the findings, we hope we can
create a new botanical drug or a new TCM prescription. Currently, our important
missions are find application of the TCM on arthritis, gastric ulcer, acnes,
osteoporosis, and chemoprevention.
Integration of three ancient purgative formulas with modern scientific
evidence-based explains.

侯文琪教授 Prof. Wen-Chi Hou
Functionality of protein, peptides, and natural products in vitro/in vivo
ORCID iD:0000-0002-9565-7018 (E-mail: wchou@tmu.edu.tw)
Protocols
 Antioxidant/anti-aging activity in vitro and in vivo
 Prevention against metabolic syndrome disorders
1. Han, C. H., Lin, Y. F., Lin, Y. S., Lee, T. L., Huang, W. J., Lin, S. Y.*, and Hou, W. C.* 2014. Effects of yam
tuber protein, dioscorin, on attenuating oxidative status and learning dysfunction in D-galactose-induced
BALB/c mice. Food Chem. Toxicol. 65, 356-363.
2. Han, C. H., Lin, Y. S., Lee, T. L., Liang, H. J.,* and Hou, W. C.* 2014. Asn-Trp dipeptides improve the
oxidative stress and learning dysfunctions in D-galactose-induced BALB/c mice. Food & Funct. 5, 2228-2236.
3. Lin, Y. S., Chen, C. R., Wu, W. H., Wen, C. L., Chang, C. I, and Hou, W. C.* 2015. Anti--glucosidase and
anti-dipeptidyl peptidase-IV activities of extracts and purified compounds from Vitis thunbergii var.
taiwaniana. J. Agric. Food Chem. 63, 6393-6401.
4. Lin, S. Y., Huang, G. C., Hsieh, Y. Y., Lin, Y. S., Han, C. H., Wen, C. L., Chang, C. I.*, and Hou, W. C.* 2015.
Vitis thunbergii var. taiwaniana extracts and purified compounds ameliorate obesity in high-fat diet-
induced obese mice. J. Agric. Food Chem. 63, 9286-9294
5 Liu, Y. H., Lin, Y. S., Huang, Y. W., Fang, S. U., Lin, S. Y.,* and Hou, W. C.* 2016. Protective effects of minor
components of curcuminoids on hydrogen peroxide-treated human HaCaT keratinocytes. J. Agric. Food
Chem. 64, 3598-3608.
6. Lin, Y. S., Han, C. H., Lin, S. Y.*, and Hou, W. C.* 2016. Synthesized peptides from yam dioscorin hydrolysis
in silico exhibit dipeptidyl peptidase-IV inhibitory activities and oral glucose tolerance improvements in
normal mice. J. Agric. Food. Chem. 64, 6451-6458.
7. Lu, Y. L., Lin, S. Y., Fang, S. U., Hsieh, Y. Y., Chen, C. R., Wen, C. L., Chang, C. I,* and Hou, W. C.* 2017. Hot-
water extracts from roots of Vitis thunbergii var. taiwaniana and identified -viniferin improve obesity in
high-fat diet-induced mice. J. Agric. Food Chem. 65, 2521-2529.
D-galactose-induced oxidative damage and
aging
Control : galactose-
induced
Blank:
untreated one

黃偉展教授 Prof. Wei-Jan Huang
Natural product and Medicinal chemistry
Synthesis and evaluation of natural product–based compounds with biological
activities
 Knowledge-based drug design
 Computation chemistry-aided drug design
 Total synthesis and structure modification of naturally occurring
compounds
Histone deacetylases (HDACs) are a family of enzymes for regulating gene
transcription and play a crucial role in biological process and diseases. Our
research focuses on developing pan and isoform-selective HDAC inhibitors
through combination of synthetic medicinal chemistry, enzyme screening panels
and molecular modeling. We are also interested in exploration for small
molecules targeting neuronal Tourret syndrome and Alzheimer disease. Some
resulting compounds and their application have been filed patent.
1. Hsu, K. C; Liu C. Y.; Lin T. E.; Hsieh J. H.; Sung T. Y.; Tseng H. J.; Yang J. M.;
Huang W. J.* Scient. Rep. 2017, 7, 3228.
2. Chao, S. W.; Su, M. Y.; Chiou L. C.; Chen, L. C.; Chang, C. I*; Huang, W. J.* J.
Nat. Prod. 2015, 78, 1969-1976.
3. Lin, C. M., Lin, Y. T., Lin, R. D., Huang, W. J.*, Lee, M. H. ACS Chem.
Neurosci. 2015, 20, 716-724.
4. Kuo, Y. H.; Huang, W. J. ; Chang C. I WIPO Patent Application
WO/2015/026935A3.
5. Huang, C. Y.; Chen, C. N.; Huang, W. J.; Lin, C. W.; Huang, J. S.; Chi,L. L.;
Chen, A. L.; Lee, C. Y.; Huang, Y. C. United States Patent 8318801.
6. Chiou, L. C.; Fan, P. C.; Huang, W. J.; Wang, S. J. United States Patent
8182844.

林若凱副教授 Associate Prof. Ruo-Kai Lin
Epigenetic and Molecular oncology research
New targeted anti-cancer drug development
 Identification of cancer associated biomarker
 Establish plasma biomarkers for early prediction/treatment response prediction
 Discovery of new targeted anti-cancer targets
Research in our laboratory is focused on (1) the identification of
novel cancer associated biomarker from clinical breast and colon
tumors. We are evaluating the potential biomarkers for early
prediction, treatment response and recurrence prediction through
serial monitoring of plasma from Taiwan breast cancer patients. (2)
We further develop new targeted anti-cancer drugs through
establishment of high-throughput drugs screening platform. We have
identified antroquinonol D induces multiple tumor suppressor genes,
while leading breast and lung cancer cell death and inhibiting
metastatic potential.
1. Chang-Lin Hsieh, Hon-Ping Ma and Ruo-Kai Lin* et. al. Alterations in Histone
Deacetylase 8 Lead to Cell Migration and Poor Prognosis in Breast Cancer. Life Sciences.
2016 (151):7-14.
2. Sheng-Chao Wang and Ruo-Kai Lin* et. al. Antroquinonol D, isolated from Antrodia
camphorate, with DNA demethylation and anti-cancer potential. Journal of Agricultural
and Food Chemistry. 2014 (62):5625-5635.
3.Ruo-Kai Lin, Lin YF, Hsu MJ, Hsieh CL, Wang CY, Huang CC, Huang WJ. Synthesis and
biological evaluation of lovastatin-derived aliphatic hydroxamates that induce reactive
oxygen species. Bioorg Med Chem Lett. 2016, 26(22):5528-5533.
4.Ruo-Kai Lin, Hung WY, Huang YF, Chang YJ, Lin CH, Chen WY, Chiu SF, Chang SC, Tsai SF
Hypermethylation of BEND5 contributes to cell proliferation and is a prognostic marker
of colorectal cancer. Oncotarget. 2017, 8(69):113431-113443.

莊國祥副教授 Associate Prof. Kuo-Hsiang Chuang
Protein/Antibody Engineering, Reporter Gene/Noninvasive Imaging, Immunology
 Bi-specific antibodies to one-step expand and arm T
cells for selective tumor therapy
 Bi-specific antibodies to enhance tumor killing
efficacy of mPEG conjugated drugs
 An endogenous reporter transgenic mouse to track
cell fates and transplant survival
 Herbal extracts to reduce the side effects of clinical
chemotherapy
1. Hao WR, Chen M, Chen YJ, Su YC, Cheng CM, Hsueh HY, Kao AP, Hsieh YC, Chang J, Tseng MY, Chuang KH*. Poly-protein G-expressing
bacteria enhance the sensitivity of immunoassays. Scientific Reports 2017 Apr 20;7(1):989. IF: 4.259
2. Su YC, Burnouf PA, Chuang KH, Chen BM, Cheng TL, Roffler SR. Conditional internalization of PEGylated nanomedicines by PEG engagers for
triple negative breast cancer therapy. Nature communications 2017 Jun 8;8:15507. IF: 12.124
3. Chen M, Cheng KW, Chen YJ, Wang CH, Cheng TC, Chang KC, Kao AP, Chuang KH*. Real-time imaging of intestinal bacterial β-glucuronidase activity
by hydrolysis of a fluorescent probe. Scientific Reports 2017 Jun 9;7(1):3142. IF: 4.259
4. Hsieh YC, Cheng TC, Wang HE, Li JJ, Lin WW, Huang CC, Chuang CH, Wang YT, Wang JY, Roffler SR, Chuang KH*, Cheng TL*. Using anti-
poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. Scientific Reports 2016 Dec 19;6:39119. IF: 4.259
5. Chuang KH, Kao CH, Roffler SR, Lu SJ, ChengTC, Wang YM, Chuang CH, Hsieh YC, Wang YT, Wang JY, Weng KY, and Cheng TL. Development of
an Anti-Methoxy Polyethylene Glycol (α-mPEG) Cell-Based Capture System to Measure mPEG and mPEGylated Molecules. Macromolecules
2014 Sep; 47(19) 6880-8. IF: 5.835
6. Kao CH, Wang JY, Chuang KH, Chuang CH, Cheng TC, Hsieh YC, Tseng YL, Chen BM, Roffler SR, Cheng TL. One-step mixing with humanized
anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. Biomaterials 2014 Dec;
35(37):9930-40. IF: 8.387
(1)
(2)

李美賢教授 Prof. Mei-Hsien Lee
Pharmacognosy
Chinese herbal medicine
Chemistry and biological activity of natural products
Representative Publications:
1.YP Lin, TY Chen, HW Tseng, MH Lee*, ST Chen. Phytochemistry 2009; 70: 1173-1181.
2.YW Mao, RD Lin, HC Hung, MH Lee*. Journal of Agricultural and Food Chemistry 2014, 62:5581−5588
3.RD Lin, MC Chen, YL Liu, YT Lin, MK Lu, FL Hsu, MH Lee*. International Journal of Molecular Sciences 2015, 16, 28598-28613.
4.CM Lin, YT Lin, RD Lin, WJ Huang, MH Lee*. ACS Chemical Neuroscience 2015, 6: 716-724.
5.CY Huang, YT Lin, HC Kuo, WF Chiou, , MH Lee*. Journal of Photochemistry & Photobiology, B: Biology 2017, 175: 244–253.
Patent:
1.MH Lee, FL Hsu, YL Liu. Extracts and compounds for inhibiting tyrosinase activity 2010 (US 7,838,049 B2)
2.MH Lee. Use of Uraria in promoting osteogenesis or providing neuroprotection. 2015 (US9044476B2)
 The analysis and extraction/purification/identification of Chinese herbal medicines/prescriptions or Taiwan
native plants
 To establish several platforms of aging-related diseases, including osteoporosis, neurodegenerative diseases,
skin aging and photoaging, for phytohemicals/nutraceuticals/drugs screening
 Preventive medicines
 The development of external herbal preparations

李佳蓉助理教授 Assistant Prof. Chia-Jung Lee, RPh, Ph.D.
Pharmacology and Pharmacokinetic Laboratory
Clinical Drug Discovery of Chinese Herbal Medicine
 Bio-assay guided fraction of TCM.
 Pharmacological study of TCM, such as anti-
inflammation, anti-arthritis and anti-acne
effects.
 Pharmacokinetics analysis of traditional
Chinese medicines by microdialysis
technology and HPLC/MS/MS analysis.
 TCM-related researches from National
Health Insurance Research Database.
1. Lee CJ, Chen LG, Liang WL, et al. Inhibitory effects of punicalagin from Punica granatum against type II
collagenase-induced osteoarthritis. Journal of Functional Foods. 2018, 41, 216-222.
2. Lee CJ, Chen LG, Liang WL, et al. Multiple Activities of Punica granatum Linne against acne vulgaris.
International Journal of Molecular Sciences, 2017, Jan 12;18(1).
3. Chien TY, Huang SK, Lee CJ, et al., International Journal of Molecular Sciences, 2016, 17, pii: E249.
4. Huang GC, Chen SY, Tsai PW, Ganzon JG, Lee CJ, et al., Drug Design, Development and Therapy. 2016, 10, 949-
57.
5. Lee CJ, Hsueh TY, Lin LC, Tsai TH. Biomedical Chromatography, 2014, 28, 901-6.
6. Tsai CF, Wang KT, Chen LG, Lee CJ, et al., Journal of Medicinal Food, 2014, 17, 479-86.
7. Lee CJ, Wu YT, Hsueh Thomas Y, Lin LC, et al., Biomedical Chromatography, 2014, 28, 630-6.

陳美全助理教授 Assistant Prof. Mei-Chuan Chen
Cancer Pharmacology, Cancer Biology, Signal transduction

胡幼圃講座教授 Chair Prof. Oliver Yoa-Pu Hu
美國佛羅里達大學藥學院藥劑學組臨床藥動學博士(1984)
Visiting Chair Professor, IBMS, Academia Sinica
Fellow, National Academy of Inventors, USA ( FNAI ;美國國家發明家學院院士 )
Fellow, American Association of Pharmaceutical Scientists, USA ( FAAPS ; 美國藥學科學家學會會士)
Co-chairman ,Regulatory Science, Special Interest Group (SIGs), The International Pharmaceutical Federation(FIP ;世界藥學會共同主席)
•Shih TY, Pai CY, Yang P, Chang WL, Wang NC, Hu, O. Y.P.*, A Novel Mechanism Underlies the Hepatotoxicity of Pyrazinamide.
Antimicrob Agents Chem. 54(4)：1685-1690, 2013. ( SCI 34/255 )
•Ting-Jen R. Cheng, Steven Weinheimer, E. Bart Tarbet, Jia-Tsrong Jan, Yih-Shyun E. Cheng, Jiun-Jie Shie, Chun-Lin Chen, Chih-An Chen,
Wei-Che Hsieh, Pei-Wei Huang, Wen-Hao Lin, Shi-Yun Wang, Jim-Min Fang*, Hu, O. Y.P*., and Chi-Huey Wong*. Development of
Oseltamivir Phosphonate Congeners as Anti-Influenza Agents. Journal of Medicinal Chemistry. 55(20)：8657-8670, 2012. ( SCI 3/59 )
• Jr-Ting Lee, Li-Heng Paob, Cheng-Huei Hsiongb, Pei-Wei Huang, Hu, O. Y.P.*. Validated liquid chromatography - tandem mass spectrometry
method for determination of totally nine probe metabolites of cytochrome P450 enzymes and UDP-glucuronosyltransferases. Talanta. 106,
200-228, 2013. ( SCI 9/75 )
•Teng-Hsu Wang, Cheng-Huei Hsiong, Hsin-Tien Ho, Tung-Yuan Shin, San-Jan Yen, Hui-Hung Wang, Jer-Yuarn Wu, Benjamin Pei-Chung Kuo,
Yuan-Tsong Chen, Hu, O. Y.P.*. Genetic Polymorphisms of Metabolic Enzymes and the Pharmacokinetics of Indapamide in Taiwanese Subjects.
AAPS J. 16(2):206-213, 2014. ( SCI 50/255 )
• Hong-Jaan Wang, Li-Heng Pao, Cheng-Huei Hsiong, Tang-Yuan Shin, Meei-Shyuan Lee, Hu, O. Y.P.* Dietary Flavonoids Modulate CYP2C to
Improve Drug Oral Bioavailability and Their Qualitative/Quantitative Structure-Activity Relationship. AAPS J, 16(2):258-68. 2014. ( SCI 50/255 )
• Shih TY, Young TH, Lee HS, Hsieh CB, Hu, O. Y.P.*, Protective Effect of Kaempferol on Isoniazid and Rifampicin-Induced Hepatotoxicity. AAPS J.
15(3): 753-62, 2013. ( SCI 50/255 )
Selective Granted Patent：
1. Hu. O. Y-P.*, et al., US Patent granted: 5,750,534, 1998.
2. Hu, O. Y-P., et.al., US Patent granted: 6,225,321, 2001.
3. Hu, O. Y-P*., et.al. European Patent granted:1149836, 2003.
4. Hu. O. Y-P*., et al., ROC patent granted: 177864, 2003.
5. Hu. O. Y-P*., et al., U.S.A. patent granted, patent no.: 8,304,394, 2012.
6. Hu, O.Y.P.*, et al., US. granted：US8,969,312 B2. 2015.
Unmet Medical Needs for TB Treatment
Kit/Chip for Prediction of High Risk SNPs of Hepatotoxicity of
Patients After Treated with Anti-TB Drugs
Dr. Hu is the owner of granted 60 world patents and the author of over a
hundred and fifty original research articles. Currently, there are one NCE new
drug has been approved for marketing and the other two on the stage of phase
III clinical trial.
 Pharmacokinetics, Pharmacodynamics and Pharmacogenetics Basis of Drug Design
and Development
 Clinical Pharmacokinetics
 Pharmaceutical Regulation and Public Health
 Fatty liver, pancreas diseases ; drug induced liver diseases.
The first designed and developed in Taiwan and NCE approved in Taiwan
Sebacoyl Dinalbuphine Ester

韓嘉莉助理教授 Assistant Prof. Chia-Li Han
Individualized Membrane Proteomics
Mass Spectrometry-based Proteogenomics
 Onco-proteogenomics analysis of cancer-specific mutated proteins
 Individualized membrane proteomics analysis of NSCLC
We aim to develop mass spectrometry (MS)-based analytical
strategies for quantitative analysis of global proteomics as
well as the under-represented membrane proteomics and
applied these proteomics technologies to discover potential
disease biomarkers for diagnosis and prognosis purposes.
CD20 1.63 1.73
BCAP29 1.43 1.73
BCAP31 3.7 3
Neutrophil
Macrophage
T helper
1
T helper
2
CD4 T
lymphocyte
B
lymphocyte
T
regulatory
CD14 1.97 0.72
FCGR3A 2.61 0.38
ICAM1 1.32 N/A
CAM1 1.18 N/A
CCR1 1.57 1.25
MAPK14 0.77 N/A
ANXA1 0.47 0.62
EEF1A1 1.81 1.04
CCR4 1.07 1.88
TGFB1 0.47 1.25
STAT3 1.2 0.82
NRAM N/A N/A
MPEG 1.1 1.14
CAPG 0.8 0.27
T helper
17
CD244 1.31 1.35
CD48 1.18 1.38
SLAMF6 1.83 1.41
IL17RA 1.23 N/A
Monocyte
CD14 1.97 0.72
ITGAX 1.24 N/A
FCGR3A 2.61 0.38
Dendritic
cell
NK cell
CD8 T
lymphocyte
ITGB2 1.55 0.84
CD44 2.41 1.16
SELL 2.71 1.04
DEFA1 0.08 0.12
CD66b 0.57 0.31
NCF2 0.73 0.46
NCF1B 0.46 0.48
ELANE 0.24 0.71
MPO 0.31 0.67
CD4 2.89 1.7
CD2 2.88 1.18
CD3D 5.2 1.91
CD3E 4.26 1.49
CD3G 2.94 1.2
ICAM1 1.32 N/A
PTPRC 2.72 0.98
CD8A 1.71 1.5
0.25
1.01
0.91
0.74
1.47
1.44
0.95
1.27
0.94
1.2
1.03
0.79
1.02
1.15
1.51
0.68
1.33
0.92
1.45
0.74
0.62
0.72
0.65
1.03
1.1
0.51
0.86
0.64
0.58
1.34
0.79
1.82
1.29
0.28
0.74
1.57
0.85
0.59
1
1.5
0.97
1.04
N/A
0.43
0.36
0.78
0.87
1.92
0.98
0.79
0.73
N/A
2.47
2.77
0.53
1.49
1.84
1.01
1.16
0.85
0.85
0.99
1.68 1.41
0.91 1.28
7.03
1.16
1.62
0.81
0.66
0.61
1.1
0.88
0.84
0.64
0.58
0.77
1.34
1.29
0.76
0.28
1.Putri DU, Feng PH, Hsu YH, Lee KY, Jiang FW, Kuo LW, Chen YJ, Han CL*,
Proteomics–Clinical Applications, 10.1002/prca.201700040 (2017).
2.Hung CL, Pan SH, Han CL, Chang CW, Hsu YL, Su CH, Shih SC, Lai YJ, Chiang Chiau
JS, Yeh HI, Liu CY, Lee HC, Lam CSP, J. Proteome Res., 16 (10), 3504-3513 (2017).
3.Tsai MT, Chen YJ, Chen CY, Tsai MH, Han CL, Chen YJ, Mersmann HJ, Ding ST5,
J Nutr. 147: 293-303 (2017)
4.Chen CL, Wu YY, Lin CF, Kuo CF, Han CL, Wang SY, Chuang WJ, Chen CY, Wu JJ,
Tsai PJ, Liu CC, Lin YS, Scientific Reports 6, 26026 (2016)
5.Che TF, Lin CW, Wu YY, Chen YJ, Han CL, Chang YL, Wu CT, Hsiao TH, Hong TM,
Yang PC, Oncotarget, 6, 37349-37366 (2015).
6.Chang CW, Chen YS, Chou SH, Han CL, Chen YJ, Yang CC, Huang CY, Lo JF*,
Cancer Res., 74, 1-15 (2014)
7.Huang TK, Han CL, Lin SI, Chen YJ, Tsai YC, Chen YR, Chen JW, Lin WY, Chen PM,
Liu TY, Chen YS, Sun CM and Chiou TJ*, Plant Cell, 25, 4044-4060 (2013)
8.Chiang SC, Han CL, Yu KH, Chen YJ, Wu KP* PLoS ONE, 8, e81079. (2013)

李松柏助理教授 Assistant Prof. Sung-Bau Lee
哥本哈根大學生物科技研創中心博士後 (University of Copenhagen, Postdoc.)
中央研究院基因體研究中心博士後 (Academia Sinica, Postdoc.)
國防醫學院生命科學研究所博士 (National Defense Medical Center, PhD)
清華大學生命科學研究所碩士 (National Tsing-Hua University, MSc)
Research Topic
• Identification & characterization of novel mechanisms controlling chromatin replication.
• Discovery of drugs that harm replication fork integrity in cancer cells
1. Feng Y, Vlassis A, Roques C, Lalonde ME, Gonzalez-Aguilera C, Lambert JP, Lee SB, Zhao X,
Alabert C, Johansen JV, Paquet, E, Yang XJ, Gingras AC, Cote J and Groth A. EMBO J 2016
2. Alabert C, Bukowski-Wills JC, Lee SB, Kustatscher G, Nakamura K, de Lima Alves F, Menard P,
Mejlvang J, Rappsilber J and Groth A. Nat Cell Biol 2014.
3. Lee, SB, Jasencakova, Z, and Groth, A. Mol Cell 2012.
4. Lee, SB, Lee, CF, Ou, DS, Chang, LH, Dulal K, Ma, CH, Huang, CF, Zhu, H, Lin YS and Juan, LJ.
Cell Res 2011.
5. Lee, CF, Ou, DS, Lee, SB, Chang, LH, Lin, RK, Li, YS, Upadhyay, AK, Cheng, X, Wang, YC, Hsu,
HS, Hsiao, M, Wu, CW and Juan, LJ. J Clin Invest 2010.
Targeting Chromatin Replication for Cancer Treatment
ControlHU
RPA/ssDNA PCNA
Faithful duplication of DNA and chromatin organization is essential to maintain
genome integrity and cell identity. Perturbation of DNA replication or genome
maintenance mechanisms can trigger replicative stress that potentially harms fork
stability and fuels tumorigenesis. By using the high-throughput screening, advance
microscopy and multi-protein complex proteomics, our laboratory aims to uncover
new factors that protect fork integrity and identify compounds to harm replication
fork integrity in cancer cells. We envision that our results could prove attractive
candidates for cancer therapy.

王三源助理教授 Assistant Prof. San-Yuan Wang
 Algorithm Development for MS-based Biomedical Signal Processing and Bioinformatics
 Metabolomics Data Analysis for Biomarker discovery
 Computational Chromatography and Mass Spectrometry
Our research focuses on Computational Mass Spectrometry and
Bioinformatics for Metabolomics, involves the development of new
algorithms and tools for removing the background noise, normalizing and
calibrating the MS data, extracting the pure signals, quantifying and
identifying the metabolites for further statistical analysis to discover potential
biomarkers for diagnosis purposes.
1.Su, B.-H.; Shen, M.-Y.; Harn, Y.-C.; Wang, S.-Y.; Schurz, A.; Lin, C.; Lin, O. A.;
Tseng, Y. J. J Cheminform 2017, 9 (1), 57.
2.Tian, T.-F.#; Wang, S.-Y. #; Kuo, T.-C.; Tan, C.-E.; Chen, G.-Y.; Kuo, C.-H.; Chen, C.-
H.; Chan, C.-C.; Lin, O. A.; Tseng, Y. J. Anal. Chem. 2016, 88 (21), 10395-10403. (#:
equal contribution)
3.Tzeng, T.-H.#; Kuo, C.-Y.#; Wang, S.-Y. #; Huang, P.-K.; Huang, Y.-M.; Hsieh, W.-C.;
Huang, Y.-J.; Kuo, P.-H.; Yu, S.-A.; Lee, S.-C.; Tseng, Y. J.; Tian, W.-C.; Lu, S.-S. IEEE
Journal of Solid-State Circuits 2016, 51 (1), 259-272. (#: equal contribution)
4.Wang, S.-Y.; Kuo, C.-H.; Tseng, Y. J. Anal. Chem. 2015, 87 (5), 3048-3055.
5.Wang, S.-Y.; Kuo, C.-H.; Yufeng J. Tseng. Anal. Chem. 2013, 85 (2), 1037-1046.
6.Wang, K.-C.; Wang, S.-Y.; Kuo, C.; Tseng, Y. J. Anal. Chem. 2013, 85 (2), 1231-
1239.
7.Wang, S.-Y.; Ho, T.-J.; Kuo, C.-H.; Tseng, Y. J. Bioinformatics 2010, 26 (18), 2338-
2339.
Bioinformatics and Biomedical Data Analysis
Computational Mass Spectrometry and MS-based Metabolomics

林恒教授 Prof. Heng Lin
Heart, kidney and antiobesity pathophysiology and drug development
 Discovery and development of small molecules towards anti obesity
 Development of small molecule for coating on stent for heart and kidney
 Development a microRNA- SPR fast urinary detection system for kidney injury
 Explore the HAX-1 gene function in heart and kidney
Research in our laboratory is focused on the design new chemical single compound for inhibition of obesity or increasing heart
or kidney function. One newly synthesized compound showed significant antiobesity on mice models. In addition, we also
construct a kidney, heart, endothelium and smooth muscle cell specific knock out mice of HAX-1 gene for studying
pathophysiology role of HAX-1 on theses organ.
pGL4-Axx 3T3-L1 stable clone
Screening
Axx -/- mice
WT mice
Axx Axx
Axx/CRE
ChREBP
Axx Axx PGC1
UCP1?
+ Axx inducer
lean lean
Representative publications
1. Chen HH, Lan YF, Li HF, Cheng CF, Lai PF, Li WH, Lin H*. Sci Rep. 2016
Jun; 6(14): 27945-59.
2. Chen HH, Lai PF, Lan YF, Cheng CF, Zhong WB, Lin YF, Chen TW, Lin
H*. J Cell Physiol. 2014 Sep; 229 (9):1202-11.
3. Lin H, Li HF, Chen HH, Lai PF, Juan SH, Chen JJ, Cheng CF. Mol
Pharmacol. 2014 May; 85(5): 682-91.
4. Lin H, Li HF, Lian WS, Chen HH, Lan YF, Lai PF, Cheng CF. Circ J. 2013
Jul; 77(10): 2586-95.
5. Lin H, Lian WS, Chen HH, Lai PF, Cheng CF. Mol Pharmacol. 2013
Aug; 84(2): 275-85.
6. Lan YF, Chen HH, Lai PF, Cheng CF, Huang YT, Lee YC, Chen TW, Lin
H*. J Am Soc Nephrol. 2012 Dec; 23(12): 2012-23.
7. Cheng CF, Lian WS, Chen SH, Lai PF, Li HF, Lan YF, Cheng WT, Lin H*.
J Cell Physiol. 2012 Jan; 227(1): 239-49.
8. Cheng CF, Lin H*. Toxicol Mech Methods. 2011 May; 21(4): 362-6.

2018 台北醫學大學藥學院教師研究專長簡介

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Ähnlich wie 2018 台北醫學大學藥學院教師研究專長簡介

Ähnlich wie 2018 台北醫學大學藥學院教師研究專長簡介 (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

2018 台北醫學大學藥學院教師研究專長簡介